Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

76.98
Delayed Data
As of Jun 24
 -4.68 / -5.73%
Today’s Change
55.00
Today|||52-Week Range
133.62
-29.02%
Year-to-Date
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Jun 24 / Zacks.com - Paid Partner Content
Better Buy: Johnson & Johnson vs. Eli Lilly
Jun 15 / MotleyFool.com - Paid Partner Content
Incyte Reports Epacadostat Combination Study Initiation
Jun 23 / Zacks.com - Paid Partner Content
Should Pfizer Buy This Beaten-Down Immuno-Oncology Company?
Jun 14 / MotleyFool.com - Paid Partner Content
Incyte Gets FDA Approval For Breakthrough Therapy Status For Its Ruxolitinib
Jun 23 / Benzinga - Paid Partner Content